After the major patent crashes of 2012, last year was more of a transitional period. Johnson & Johnson, Novartis, Roche, GlaxoSmithKline, Eli Lilly and Bayer saw their revenues rise, although only J&J and Bayer had an appreciable change. Bayer's pharma revenues, combined with its consumer health unit, saw revenue growth of 7.6% based on dollars. J&J's number was up 6.7%, driven in large part by its pharma division. The others were flat or had growth of less than 3%.

 

Pfizer, Sanofi, Merck & Co. and AstraZeneca were on the revenue-eroding end of the spectrum. Patent losses on blockbusters figured into most of the declines. Merck, whose revenues were off 6.8%, lost the patent on Singulair. Pfizer, which has yet to get past the sales erosion from the 2011 patent loss of Lipitor, saw its revenues fade 6%. Interestingly, Lipitor generics also rained on AstraZeneca's revenue parade, cutting sales of its cholesterol-lowering drug Crestor by 9% for the year; AZ's revenues were off 8% across the board. Sanofi's revenues were down 5.7%, undermined by a host of issues, including the patent loss on Plavix.

 

Click on the hyperlinks below to view report results for each company.

 

  Company name

2012 revenue

(USD)

2013 revenue

(USD)

10-K

available?

1 Johnson & Johnson  67.200

71.312

View

2 Novartis  56.673

57.920 

-

Roche  47.800

52.307 

-

Pfizer  58.986

51.584

View

Sanofi 47.769

45.078

-

GlaxoSmithKline  39.925

44.146

-

Merck  47.267

44.033

View

Bayer HealthCare  24.300

25.969 

-

AstraZeneca  27.970

25.711 

-

10  Eli Lilly  22.603

23.113

View

 

Figures have been drawn from companies' filings with the Securities and Exchange Commission, their annual reports, and information provided during earnings calls. Figures originally posted by FiercePharma.